Home › Companies › C4 Therapeutics, Inc. › 2024-2025
Compiled from SEC Form N-PX filings and C4 Therapeutics, Inc.’s Form 8-K, filed June 18, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 18, 2025: 6 items on C4 Therapeutics, Inc.’s Form 8-K, filed June 18, 2025: 2 approved · 4 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025
Explore C4 Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are C4 Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Ronald Harold Wilfred Cooper | 38,963,561 | -- | -- | 10,829,443 | 10,514,206 | 78% | Not verified | — |
| Elect Director: Donna Grogan, M.D. | 42,592,170 | -- | -- | 7,200,834 | 10,514,206 | 86% | Not verified | — |
| Elect Director: Steven Hoerter | 49,604,182 | -- | -- | 188,822 | 10,514,206 | 99.6% | Not verified | — |
| b) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. | 48,851,725 | 889,711 | 51,568 | -- | 10,514,206 | 98% | Not verified | — |
| c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. | 60,179,540 | 79,871 | 47,799 | -- | 0 | 99.8% | Approved | — |
| d) The Company's stockholders approved the amendment to the Company's Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000. | 39,547,136 | 20,664,896 | 95,178 | -- | 0 | 66% | Approved | — |
Source: C4 Therapeutics, Inc., Form 8-K, filed with the SEC on June 18, 2025 — read the filing on EDGAR.
Each item below shows how the 107 asset managers that disclosed a C4 Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: To elect three Class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Donna Grogan, M.D.
C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Donna Grogan, M.D.”): 42,592,170 for, 7,200,834 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 9,683,455 for, 760,581 withheld, 836,959 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 5,629,250 | 0 | 0 | 0 | For |
| Vanguard | 2,654,692 | 0 | 0 | 0 | For |
| Fidelity | 1,068,882 | 0 | 0 | 106,831 | Mixed |
| BlackRock | 0 | 0 | 698,450 | 0 | Abstain |
| Charles Schwab | 0 | 0 | 0 | 478,424 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 99,140 | 0 | Abstain |
| Equitable | 0 | 0 | 0 | 76,427 | Withhold |
| Invesco | 48,870 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 44,947 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,500 | 0 | 0 | 0 | For |
| Northern Trust | 35,768 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 35,561 | Withhold |
| Pacific Life | 0 | 0 | 0 | 32,960 | Withhold |
| AIG/SunAmerica | 31,510 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 0 | 26,684 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 22,677 | 0 | 0 | 0 | For |
| Voya | 17,322 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 15,100 | 0 | 0 | 0 | For |
| ProShares | 14,860 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 13,525 | Withhold |
| Jackson National | 0 | 0 | 12,685 | 0 | Abstain |
| PFM Multi-Manager Series Trust | 11,600 | 0 | 0 | 0 | For |
| John Hancock | 10,067 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 9,600 | Withhold |
| DWS | 9,555 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
Combines 3 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: To elect three Class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Ronald Harold Wilfred Cooper
C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Ronald Harold Wilfred Cooper”): 38,963,561 for, 10,829,443 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 9,833,515 for, 566,177 withheld, 881,303 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 5,629,250 | 0 | 0 | 0 | For |
| Vanguard | 2,654,692 | 0 | 0 | 0 | For |
| Fidelity | 1,068,882 | 0 | 0 | 106,831 | Mixed |
| BlackRock | 0 | 0 | 698,450 | 0 | Abstain |
| Charles Schwab | 478,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 99,140 | 0 | Abstain |
| Equitable | 0 | 0 | 0 | 76,427 | Withhold |
| Invesco | 0 | 0 | 0 | 48,870 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 44,947 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 43,500 | Withhold |
| Northern Trust | 0 | 0 | 0 | 35,768 | Withhold |
| Global X | 0 | 0 | 0 | 35,561 | Withhold |
| Pacific Life | 0 | 0 | 0 | 32,960 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 31,510 | Withhold |
| Bridge Builder Trust | 0 | 0 | 26,684 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 22,677 | 0 | Abstain |
| Voya | 0 | 0 | 0 | 17,322 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 15,100 | Withhold |
| ProShares | 0 | 0 | 0 | 14,860 | Withhold |
| Nationwide | 0 | 0 | 0 | 13,525 | Withhold |
| Jackson National | 0 | 0 | 12,685 | 0 | Abstain |
| PFM Multi-Manager Series Trust | 0 | 0 | 11,600 | 0 | Abstain |
| John Hancock | 0 | 0 | 10,067 | 0 | Abstain |
| SEI | 0 | 0 | 0 | 9,600 | Withhold |
| DWS | 0 | 0 | 0 | 9,555 | Withhold |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: To elect three Class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Steven Hoerter
C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Steven Hoerter”): 49,604,182 for, 188,822 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 11,174,164 for, 106,831 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 5,629,250 | 0 | 0 | 0 | For |
| Vanguard | 2,654,692 | 0 | 0 | 0 | For |
| Fidelity | 1,068,882 | 0 | 0 | 106,831 | Mixed |
| BlackRock | 698,450 | 0 | 0 | 0 | For |
| Charles Schwab | 478,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 99,140 | 0 | 0 | 0 | For |
| Equitable | 76,427 | 0 | 0 | 0 | For |
| Invesco | 48,870 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 44,947 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,500 | 0 | 0 | 0 | For |
| Northern Trust | 35,768 | 0 | 0 | 0 | For |
| Global X | 35,561 | 0 | 0 | 0 | For |
| Pacific Life | 32,960 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,510 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 26,684 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,677 | 0 | 0 | 0 | For |
| Voya | 17,322 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 15,100 | 0 | 0 | 0 | For |
| ProShares | 14,860 | 0 | 0 | 0 | For |
| Nationwide | 13,525 | 0 | 0 | 0 | For |
| Jackson National | 12,685 | 0 | 0 | 0 | For |
| PFM Multi-Manager Series Trust | 11,600 | 0 | 0 | 0 | For |
| John Hancock | 10,067 | 0 | 0 | 0 | For |
| SEI | 9,600 | 0 | 0 | 0 | For |
| DWS | 9,555 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
Combines 2 wordings of this item as funds reported it.
66% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000
C4 Therapeutics, Inc.’s own tally for this item (“d) The Company's stockholders approved the amendment to the Company's Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.”): 39,547,136 for, 20,664,896 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “d) The Company's stockholders approved the amendment to the Company's Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.”
Support: 66% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 9,576,592 for, 1,704,403 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 5,629,250 | 0 | 0 | 0 | For |
| Vanguard | 2,654,692 | 0 | 0 | 0 | For |
| Fidelity | 0 | 1,175,713 | 0 | 0 | Against |
| BlackRock | 698,450 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 478,424 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 99,140 | 0 | 0 | 0 | For |
| Equitable | 76,427 | 0 | 0 | 0 | For |
| Invesco | 48,870 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 44,947 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,500 | 0 | 0 | 0 | For |
| Northern Trust | 35,768 | 0 | 0 | 0 | For |
| Global X | 0 | 35,561 | 0 | 0 | Against |
| Pacific Life | 32,960 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,510 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 26,684 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,677 | 0 | 0 | 0 | For |
| Voya | 17,322 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 15,100 | 0 | 0 | 0 | For |
| ProShares | 14,860 | 0 | 0 | 0 | For |
| Nationwide | 8,703 | 4,822 | 0 | 0 | Mixed |
| Jackson National | 12,685 | 0 | 0 | 0 | For |
| PFM Multi-Manager Series Trust | 11,600 | 0 | 0 | 0 | For |
| John Hancock | 10,067 | 0 | 0 | 0 | For |
| SEI | 0 | 9,600 | 0 | 0 | Against |
| DWS | 9,555 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: TO CAST A NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
C4 Therapeutics, Inc.’s own tally for this item (“b) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.”): 48,851,725 for, 889,711 against, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 5,629,250 | 0 | 0 | 0 | For |
| Vanguard | 2,654,692 | 0 | 0 | 0 | For |
| Fidelity | 1,068,882 | 106,831 | 0 | 0 | Mixed |
| BlackRock | 698,450 | 0 | 0 | 0 | For |
| Charles Schwab | 478,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 99,140 | 0 | 0 | 0 | For |
| Equitable | 28,627 | 47,800 | 0 | 0 | Mixed |
| Invesco | 48,870 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 44,947 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,500 | 0 | 0 | 0 | For |
| Northern Trust | 35,768 | 0 | 0 | 0 | For |
| Global X | 35,561 | 0 | 0 | 0 | For |
| Pacific Life | 32,960 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,510 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 26,684 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,677 | 0 | 0 | 0 | For |
| Voya | 17,322 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 15,100 | 0 | 0 | 0 | For |
| ProShares | 14,860 | 0 | 0 | 0 | For |
| Nationwide | 13,525 | 0 | 0 | 0 | For |
| Jackson National | 0 | 12,685 | 0 | 0 | Against |
| PFM Multi-Manager Series Trust | 11,600 | 0 | 0 | 0 | For |
| John Hancock | 10,067 | 0 | 0 | 0 | For |
| SEI | 9,600 | 0 | 0 | 0 | For |
| DWS | 9,555 | 0 | 0 | 0 | For |
Fund voting reports, all 37 managers: 11,097,865 for, 183,130 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 7,098,133 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 6,830,300 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 6,616,264 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 5,912,485 | 0 | 0 | 0 | For |
| SAMLYN CAPITAL, LLC | 3,009,719 | 0 | 0 | 0 | For |
| BlackRock | 1,731,774 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,117,888 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,047,630 | 0 | 0 | 0 | For |
| State Street | 580,834 | 0 | 0 | 0 | For |
| Charles Schwab | 478,424 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 417,569 | 0 | 0 | 0 | For |
| Two Sigma | 341,990 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 239,242 | 0 | 0 | 0 | For |
| Northern Trust | 239,095 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 204,505 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 168,225 | 0 | 0 | 0 | For |
| Fidelity | 0 | 121,773 | 0 | 0 | Against |
| Invesco | 74,627 | 0 | 0 | 0 | For |
| AQR | 64,579 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 64,067 | 0 | 0 | 0 | For |
| Vanguard | 61,926 | 0 | 0 | 0 | For |
| Atom Investors LP | 54,621 | 0 | 0 | 0 | For |
| Renaissance | 54,052 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 49,847 | 0 | 0 | 0 | For |
Institutional-manager reports, all 84 managers: 37,931,374 for, 219,404 against. Showing the 25 largest; see all in the interactive database.
99.8% Approved · of votes cast
Description as filed by funds: TO RATIFY THE ENGAGEMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.
C4 Therapeutics, Inc.’s own tally for this item (“c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 60,179,540 for, 79,871 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 11,280,995 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 5,629,250 | 0 | 0 | 0 | For |
| Vanguard | 2,654,692 | 0 | 0 | 0 | For |
| Fidelity | 1,175,713 | 0 | 0 | 0 | For |
| BlackRock | 698,450 | 0 | 0 | 0 | For |
| Charles Schwab | 478,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 99,140 | 0 | 0 | 0 | For |
| Equitable | 76,427 | 0 | 0 | 0 | For |
| Invesco | 48,870 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 44,947 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,500 | 0 | 0 | 0 | For |
| Northern Trust | 35,768 | 0 | 0 | 0 | For |
| Global X | 35,561 | 0 | 0 | 0 | For |
| Pacific Life | 32,960 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,510 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 26,684 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,677 | 0 | 0 | 0 | For |
| Voya | 17,322 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 15,100 | 0 | 0 | 0 | For |
| ProShares | 14,860 | 0 | 0 | 0 | For |
| Nationwide | 13,525 | 0 | 0 | 0 | For |
| Jackson National | 12,685 | 0 | 0 | 0 | For |
| PFM Multi-Manager Series Trust | 11,600 | 0 | 0 | 0 | For |
| John Hancock | 10,067 | 0 | 0 | 0 | For |
| SEI | 9,600 | 0 | 0 | 0 | For |
| DWS | 9,555 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,007,083 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | WASATCH FUNDS TRUST | 7.93% |
| 2 | Vanguard | 3.74% |
| 3 | Fidelity | 1.66% |
| 4 | BlackRock | 0.98% |
| 5 | Charles Schwab | 0.67% |
| 6 | QUANTITATIVE MASTER SERIES LLC | 0.14% |
| 7 | Equitable | 0.11% |
| 8 | Invesco | 0.07% |
| 9 | BRIDGEWAY FUNDS INC | 0.06% |
| 10 | Lincoln Financial | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Lynx1 Capital Management LP | 10.00% |
| 2 | ORBIMED ADVISORS LLC | 9.62% |
| 3 | WASATCH ADVISORS LP | 9.32% |
| 4 | Soleus Capital Management, L.P. | 8.33% |
| 5 | SAMLYN CAPITAL, LLC | 4.24% |
| 6 | BlackRock | 2.44% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.57% |
| 8 | Bain Capital Life Sciences Investors, LLC | 1.57% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.48% |
| 10 | State Street | 0.82% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Sirenia Capital Management LP | 33.10% | 13G |
| Soleus Capital Master Fund, L.P. | 14.59% | 13G |
| RA Capital Management, L.P. | 13.30% | 13G |
| Morgan Stanley | 12.64% | 13G |
| Lynx1 Capital Management LP | 10.00% | 13G |
| BCLS II Equity Opportunities, LP | 8.53% | 13G |
| BlackRock | 7.44% | 13F |
| Betta Investment (Hong Kong) Limited | 6.86% | DEF14A |
| Wasatch Advisors LP | 6.45% | 13G |
| Entities Affiliated with OrbiMed | 6.17% | DEF14A |
Percentages above are of 71,007,083 shares outstanding, as reported by C4 Therapeutics, Inc. on its Form 10-Q dated May 1, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from C4 Therapeutics, Inc.’s 10-Q dated May 1, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At C4 Therapeutics, Inc.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 107 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 701 separate fund positions. On the most widely held item on that ballot — TO CAST A NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: C4 Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2025.
C4 Therapeutics, Inc. proxy season coverage: 2024-2025 (this page).
Download data (CSV): ballot items · votes by manager · column guide.